In recent years, immune checkpoint blocking therapy has made important progress, and immune checkpoint blocking therapy targeting the PD-1/PD-L1 pathway has achieved remarkable efficacy in the treatment of human solid tumors such as malignant melanoma, non-small-cell lung cancer, renal cell cancer, lymphoma, and breast cancer [4]. Here, CD274 is linked to non-small cell lung carcinoma.